Literature DB >> 25317651

[Significance of insulin analogues in the treatment of people with type 2 diabetes].

B Gallwitz1, D Westrup2, G-W Schmeisl3.   

Abstract

Assessment of the significance of the different insulins used in type 2 diabetes mellitus is of fundamental importance for routine treatment. Compared with human insulin, rapid acting insulin analogues have a faster uptake and a higher peak effect as well as a shorter duration of action. Long acting insulin analogues have a flatter action profile and a longer duration of action than NPH insulin. Consequently, insulin analogues generally allow an improved glycaemic control to be achieved. Moreover, differences relating to practical aspects are of importance (snacks and interval between injection and meals in the case of short acting insulin as well as mixing of suspensions and number of injections in the case of long acting insulins). The consequences for clinical practice are seen differently by countries as shown by a prescription rate of 50 % for insulin analogues in Germany compared with approximately 90 % in certain other European countries. One of the main reasons why questions remain is the lack of meaningful long-term studies on diabetes-related complications. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25317651     DOI: 10.1055/s-0034-1387263

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

Review 1.  Pharmacological Properties of Faster-Acting Insulin Aspart.

Authors:  Torben Biester; Olga Kordonouri; Thomas Danne
Journal:  Curr Diab Rep       Date:  2017-09-23       Impact factor: 4.810

Review 2.  Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons.

Authors:  Naeema Hanif; Hezhou Wu; Peizhou Xu; Yun Li; Amir Bibi; Asma Zulfiqar; Muhammad Zafar Iqbal; Muhammad Tahir; Xiangyang Zhang; Asif Ali
Journal:  Curr Issues Mol Biol       Date:  2022-02-11       Impact factor: 2.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.